Company Overview of FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. discovers and develops medicines in cancer and other genetically-driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company has a strategic partnership with Celgene Corporation. FORMA Therapeutics, Inc. was formerly known as Forma Pharmaceuticals, Inc. and changed its name to FORMA Therapeutics, Inc. in February 2008. The company was incorporated in 2007 and is based in Watertown, Massachusetts. It has additional chemistry operations in Branford, Connecticut.
500 Arsenal Street
Watertown, MA 02472
Founded in 2007
Key Executives for FORMA Therapeutics, Inc.
Co-Founder, Chief Executive Officer, President and Director
Co-Founder and Vice President of Discovery Biology
Head of Biomolecular Screening and Executive Director
Compensation as of Fiscal Year 2014.
FORMA Therapeutics, Inc. Key Developments
FORMA Therapeutics, Inc. Presents at Boston CEO Conference, May-26-2015 through May-27-2015
Apr 16 15
FORMA Therapeutics, Inc. Presents at Boston CEO Conference, May-26-2015 through May-27-2015. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Presentation Date & Speakers: May-26-2015, Steven Tregay, Co-Founder, Chief Executive Officer, President and Director. May-27-2015, Steven Tregay, Co-Founder, Chief Executive Officer, President and Director.
FORMA Therapeutics, Inc. Appoints Paolo Paoletti as a Board of Directors
Apr 13 15
FORMA Therapeutics announced the appointment of Paolo Paoletti as a Board of Directors. In addition to serving as a director, Dr. Paoletti will also lead FORMA’s Research & Development Committee as its chairperson; in this capacity, his strategic clinical and research insights will be applied to FORMA’s target family drug discovery paradigm. Dr. Paoletti held several executive leadership roles in oncology at GSK, including Head of Oncology R&D Unit, Member of the Executive Board for Portfolio Investment and Chairman of the Oncology Portfolio Board. In his global leadership roles, he maintained the accountability for GSK’s entire oncology business and was responsible for drug discovery from target identification through registration, including product life cycle management and commercial strategy.
FORMA Therapeutics and Cancer Research Technology Form Two Virtual Companies to Advance Deubiquitination Assets
Mar 23 15
FORMA Therapeutics and Cancer Research Technology Ltd. announced the formation of two new virtual Asset Discovery and Development Companies (ADDCos) with novel chemical matter targeting undisclosed deubiquitinating enzymes (DUBs). ADDCos are virtual companies seeking to achieve rapid innovation in a compelling scientific area through the collaboration of academic thought leaders, FORMA drug discovery scientists and a world class development network. This builds on an ongoing initiative between FORMA and CRT, the commercial arm of Cancer Research UK, to discover innovative tools, technologies and therapeutic drug candidates against a variety of DUBs that regulate protein homeostasis. Under their agreement, FORMA is pairing its ultra-efficient drug discovery capabilities with expertise from CRT's Discovery Laboratories (CRT-DL) in translating academic discoveries and the exclusive world class academic network of Cancer Research UK scientists.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|